New anticoagulants - Their clinical significance;Neue antikoagulanzien - Bedeutung für die Praxis

Therapeutische Umschau

Volumn 60, Issue 1, 2003, Pages 19-23

  Haas, S ^a  

^a Inst F Exp Onkol/Therapieforsch   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A INHIBITOR; ENOXAPARIN; FONDAPARINUX; HEPARIN; XIMELAGATRAN;

BLEEDING; CLINICAL TRIAL; DRUG BINDING; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; OUTPATIENT DEPARTMENT; REVIEW; THROMBOEMBOLISM;

EID: 0037257528     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930.60.1.19     Document Type: Review

References (29)

1. Choay J, Lormeau JC, Petitou M, Sinay P, Fareed J. Structural studies on a biologically active hexasaccharide obtained from heparin. Ann NY Acad Sci 1981; 370: 644-9.
2. Holmer E, Kurachi K, Söderström G. The molecular weight dependence of the rate enhancing effect of heparin on the inhibition of thrombin, factor Xa, IXa, XIa, XIIa and kallikrein by antithrombin. Biochem J 1981; 193: 395-400.
3. Yin ET. Effect of heparin on the neutralization of factor Xa and thrombin by the plasma alpha-II globulin inhibitor. Thromb Diathes Haemorrh 1975; 33: 43-50.
4. Choay J, Petitou M, Lormeau JC, Sinay P, Casu B, Gatti G. Structure activity relationships in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti factor Xa activity. Biochem Biophys Res Commun 1983; 116: 492-9.
5. Walsh PN. Roles of platelets and factor XI in the initiation of blood coagulation by thrombin. Thromb Haemost 2001; 86: 75-82.
6. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-91.
7. Kumar R, Beguin S, Hemker C. The effect of fibrin clots and clot-bound thrombin on the development of platelet coagulant activity. Thromb Haemost 1995; 74: 962-8.
8. Kumar R, Beguin S, Hemker C. The influence of fibrinogen and fibrin on thrombin generation - evidence for feedback activation of the clotting system by clot bound thrombin. Thromb Haemost 1994; 72: 713-21.
9. Nesheim M, Wang W, Boffa M, Nagashima M, Morser J, Bajzar L. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost 1997; 78: 387-91.
10. Elalamy I, Lecrubier C, Potevin F et al. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia. Thromb Haemost 1995; 74: 1384-5.
11. Turpie AGG, Gallus AS, Hock JA for the Pentasaccharide Investigators. A synthetic pentasaccharide for the prevention of deep vein thrombosis after total hip replacement. N Engl J Med 2001; 344: 619-25.
12. Lassen MR, Bauer KA, Eriksson BI et al. Fondaparinux versus Enoxaparin for the prevention of venous thromboembolism in elective hip replacement surgery. A randomised double-blind comparison. Lancet 2002; 359: 1715-20.
13. Turpie AGG, Bauer KA, Eriksson BI et al. A randomised double blind comparison of Fondaparinux with Enoxaparin for the prevention of venous thromboembolism after elective hip replacement surgery. Lancet 2002; 359: 1721-26.
14. Eriksson BI, Bauer KA, Lassen MR et al. Fondaparinux compared with Enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001, 345: 1298-304.
15. Bauer KA, Eriksson BI, Lassen MR et al. Fondaparinux compared with Enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001; 345: 1305-10.
16. AGG Turpie: Overview of the clinical results of pentasaccharide in major orthopedic surgery. Haematologica 2001; 86 (Suppl): 59-62.
17. The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure antifactor Xa activity. Circulation 2000; 102: 2726-31.
18. Gustafsson D, Nystrom J, Carlsson S et al. The direct thrombin inhibitor melagatran and its oral prodrug 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001; 101: 171-81.
19. Fager G, Eriksson-Lepkowska M, Frison L et al. Influence of acetylslicyclic acid on the pharmacodynamics and pharmacokinetics of melagatran, the active form of the direct thrombin inhibitor H376/95 (Abstract). Eur Heart J 2000; 21: 441.
20. Eriksson-Lepkowska M, Thuresson A, Bylock A, Frison L, Ericksson UG. The effect of the oral direct thrombin inhibitor, ximelagatran, on the pharmacokinetics of diazepam in healthy male volunteers (Abstract). Thromb Haemost 2001; (Suppl): P785.
21. Eriksson-Lepkowska M, Thuresson A, Bylock A, Frison L, Eriksson UG. The effect of oral direct thrombin inhibitor, ximelagatran, on the pharmacokinetics and pharmacodynamics of diclofenac in healthy male volunteers (Abstract). Thromb Haemost 2001; (Suppl): P786.
22. Johansson S, Bylock A, Eriksson-Lepkowska M, Thuresson A, Frison L, Ericksson UG. The effect of the oral direct thrombin inhibitor, ximelagatran, on the pharmacokinetics of nifedipine in healthy male volunteers (Abstract). Thromb Haemost 2001; (Suppl): P784.
23. Elg M, Gustafsson D, Carlsson S. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. Thromb Res 1999; 94: 187-97.
24. Klement P, Carlsson S, Liao P et al. Melagatran, a safe alternative to hirudin in prevention of arterial thrombosis. Thromb Haemost 2001; (Suppl): P3078.
25. Gustafsson D, Nystrom J, Carlsson S et al. The direct thrombin inhibitor melagatran and its oral prodrug 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001; 101: 171-81.
26. Eriksson BI, Bergqvist D, Kälebo P et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002; 360: 1441-47.
27. Heit JA, Colwell CW, Francis CW et al. Comparison of the oral direct thrombin inhibitor Ximelagatrun with Enoxaparin as prophylaxis against venous thromboembolism after total knee replacement. Arch Intern Med 2001; 161: 2215-21.
28. Schulman S, Wahlander K, Gustafsson D et al. Efficacy and tolerability of the novel, oral direct thrombin inhibitor Ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis. Blood 2001; (suppl): 1875, abstract.
29. Petersen P. First experience with the oral direct thrombin inhibitor H376/95 compared with warfarin in patients with non-valvular atrial fibrillation (NVAF) (Abstract). J Gen Int Med 2001; 16: (s1) 164.